• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于检测结石“活性”的新型尿液检测方法。

A new urinary test for stone "activity".

作者信息

Hallson P C, Rose G A

出版信息

Br J Urol. 1978 Dec;50(7):442-8. doi: 10.1111/j.1464-410x.1978.tb06188.x.

DOI:10.1111/j.1464-410x.1978.tb06188.x
PMID:753493
Abstract

Rapid evaporation of urine to osmolarity 1200 results in a high incidence of envelope Wedellite and calcium phosphate crystals. The Wedellite crystals closely resemble those seen in untreated urine samples of stone formers. The incidence of crystalluria produced by these tests is higher in the stone formers than in the normal subjects, reduced by thiazides and increased by cellulose phosphate; combined thiazide and cellulose phosphate therapy was most effective in reducing crystalluria. Simple calcium and oxalate concentration products were calculated and did not correlate well with incidence of calcium oxalate crystalluria. Although the product is important, inhibitors of crystal formation must be equally important. It is postulated, but not proven, that the evaporation tests may indicate normal subjects at risk to stone formation when exposed to chronic dehydration and whether a stone former is still metabolically active.

摘要

尿液快速蒸发至渗透压1200会导致包膜水草酸钙和磷酸钙晶体的高发生率。水草酸钙晶体与结石形成者未经处理的尿液样本中所见的晶体非常相似。这些测试产生的结晶尿发生率在结石形成者中高于正常受试者,噻嗪类药物可降低其发生率,而磷酸纤维素可增加其发生率;噻嗪类药物和磷酸纤维素联合治疗在减少结晶尿方面最有效。计算了简单的钙和草酸盐浓度乘积,其与草酸钙结晶尿的发生率相关性不佳。虽然该乘积很重要,但晶体形成抑制剂肯定同样重要。据推测(但未得到证实),蒸发测试可能表明正常受试者在暴露于慢性脱水时存在结石形成风险,以及结石形成者是否仍处于代谢活跃状态。

相似文献

1
A new urinary test for stone "activity".一种用于检测结石“活性”的新型尿液检测方法。
Br J Urol. 1978 Dec;50(7):442-8. doi: 10.1111/j.1464-410x.1978.tb06188.x.
2
Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment.正常受试者以及接受和未接受噻嗪类药物与磷酸纤维素治疗的结石形成者的结晶尿情况。
Br J Urol. 1976;48(7):515-24. doi: 10.1111/j.1464-410x.1976.tb06696.x.
3
Studies on crystalluria in calcium oxalate stone formers.草酸钙结石患者的结晶尿研究。
Urol Res. 1984;12(2):103-6. doi: 10.1007/BF00257173.
4
Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects.结石患者和正常受试者肾尿与膀胱尿中草酸钙结晶尿的研究。
Urol Int. 1998;60(1):41-6. doi: 10.1159/000030201.
5
Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats.噻嗪类药物可降低遗传性高钙尿结石形成大鼠的透钙磷石过饱和度,但不能降低草酸钙过饱和度及结石形成。
J Am Soc Nephrol. 2005 Feb;16(2):417-24. doi: 10.1681/ASN.2004070543. Epub 2005 Jan 12.
6
Urinary oxalate in summer and winter in normal subjects and in stone-forming patients with idiopathic hypercalciuria, both untreated and treated with thiazide and/or cellulose phosphate.正常受试者以及患有特发性高钙尿症的结石形成患者在夏季和冬季的尿草酸情况,这些患者未接受治疗、接受噻嗪类药物和/或磷酸纤维素治疗。
Urol Res. 1976;4(4):169-73. doi: 10.1007/BF00262350.
7
The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers.对于复发性结石形成者的治疗而言,高钙尿症机制的定义是必要的。
Contrib Nephrol. 1982;33:136-51. doi: 10.1159/000407071.
8
Calcium stone disease: an overview.钙结石病:概述
J Urol. 1986 Jan;135(1):1-9. doi: 10.1016/s0022-5347(17)45497-8.
9
Measurement of calcium phosphate crystalluria: influence of pH and osmolality and invariable presence of oxalate.磷酸钙结晶尿的测量:pH值和渗透压的影响以及草酸盐的恒定存在。
Br J Urol. 1989 Nov;64(5):458-62. doi: 10.1111/j.1464-410x.1989.tb05276.x.
10
Prophylactic treatment of renal calcium stones. Experiences with dietary advice, cellulose, phosphate and thiazides.肾钙结石的预防性治疗。饮食建议、纤维素、磷酸盐及噻嗪类药物的应用经验。
Scand J Urol Nephrol Suppl. 1980;53:239-52.

引用本文的文献

1
Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis.使用钙荧光标记和纳米颗粒跟踪分析估算人体尿液中的纳米晶体。
J Vis Exp. 2021 Feb 9(168). doi: 10.3791/62192.
2
Dietary Oxalate Induces Urinary Nanocrystals in Humans.膳食草酸盐会在人体中诱导产生尿纳米晶体。
Kidney Int Rep. 2020 May 7;5(7):1040-1051. doi: 10.1016/j.ekir.2020.04.029. eCollection 2020 Jul.
3
Upper metastable limit osmolality of urine as a predictor of kidney stone formation in children.尿的上亚稳渗透压极限作为预测儿童肾结石形成的指标。
Urolithiasis. 2019 Apr;47(2):155-163. doi: 10.1007/s00240-018-1041-2. Epub 2018 Jan 22.
4
In vitro calcium oxalate crystallisation methods.体外草酸钙结晶方法。
Urol Res. 2006 Apr;34(2):139-45. doi: 10.1007/s00240-005-0027-z. Epub 2006 Jan 14.
5
Selected medical aspects of the problem of calcium oxalate stones: a review.草酸钙结石问题的相关医学要点综述
J R Soc Med. 1982 Nov;75(11):897-9. doi: 10.1177/014107688207501115.
6
Tamm-Horsfall mucoprotein promotes calcium phosphate crystal formation in whole urine: quantitative studies.
Urol Res. 1984;12(4):217-21. doi: 10.1007/BF00256807.
7
Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine.
Urol Res. 1983;11(4):151-4. doi: 10.1007/BF00256361.
8
Measurement of the risk of calcium oxalate crystallization in urine.尿液中草酸钙结晶风险的测量。
Urol Res. 1985;13(6):297-300. doi: 10.1007/BF00262660.
9
Clinical investigations.临床研究。
Urol Res. 1990;18 Suppl 1:S31-5. doi: 10.1007/BF00301525.
10
Inhibition of calcium oxalate crystallization by urinary macromolecules.尿大分子对草酸钙结晶的抑制作用。
Urol Res. 1991;19(3):165-9. doi: 10.1007/BF00303743.